Aquanaz Tablet
Product Images NDC 29978-587

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 1 technical images submitted to the FDA as part of the official labeling for Aquanaz (NDC 29978-587). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Capital Pharmaceutical, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panelndc 29978-587-01newaquanaztabletstriple Combination Relief:cough Suppressant: Dextromethorphan Hbr 15 mgexpectorant: Guaifenesin 400 mgdecongestant: Phenylephrine HCl 10 mg100 Tablets (Aquanaz Tablets 01)

Principal Display Panelndc 29978-587-01newaquanaztabletstriple Combination Relief:cough Suppressant: Dextromethorphan Hbr 15 mgexpectorant: Guaifenesin 400 mgdecongestant: Phenylephrine HCl 10 mg100 Tablets (Aquanaz Tablets 01)
This is a drug information leaflet with dosage instructions and warnings for a medication labelled as NDC 29978-587-01. The medication is a triple combination relief containing Phenylephrine HCL 10mg, Dextromethorphan HBR 15mg and Guaifenesin 400mg. It is recommended for adults and children above 12 years of age and should be taken every 4 hours as needed, without exceeding 4 tablets within 24 hours or when directed by a doctor. It is advised to consult with a doctor before using this medication if you have heart disease, high blood pressure, thyroid disease, diabetes, difficulty in urination or prostate enlargement. Additionally, if the patient is currently taking prescription monoamine oxdase inblor, they should speak to a healthcare professional before use. Keep out of reach of children. The inactive ingredients in the medication include F&C Blue # 2, Microcrystalline Cellulose, Silicon Dioxide, Guaifenesin, and Stearic Acid. If new symptoms occur or there is no improvement in the condition, the medication should be discontinued.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.